181 related articles for article (PubMed ID: 18056192)
1. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.
Dudek AZ; Yunis C; Harrison LI; Kumar S; Hawkinson R; Cooley S; Vasilakos JP; Gorski KS; Miller JS
Clin Cancer Res; 2007 Dec; 13(23):7119-25. PubMed ID: 18056192
[TBL] [Abstract][Full Text] [Related]
2. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma.
Dummer R; Hauschild A; Becker JC; Grob JJ; Schadendorf D; Tebbs V; Skalsky J; Kaehler KC; Moosbauer S; Clark R; Meng TC; Urosevic M
Clin Cancer Res; 2008 Feb; 14(3):856-64. PubMed ID: 18245549
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous pharmacodynamics of a toll-like receptor 7 agonist, 852A, in humans.
Astry C; Birmachu W; Harrison LI; Meng TC
J Clin Pharmacol; 2008 Jun; 48(6):755-62. PubMed ID: 18401016
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans.
Harrison LI; Astry C; Kumar S; Yunis C
J Clin Pharmacol; 2007 Aug; 47(8):962-9. PubMed ID: 17660481
[TBL] [Abstract][Full Text] [Related]
5. Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies.
Weigel BJ; Cooley S; DeFor T; Weisdorf DJ; Panoskaltsis-Mortari A; Chen W; Blazar BR; Miller JS
Am J Hematol; 2012 Oct; 87(10):953-6. PubMed ID: 22718533
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of pazopanib in patients with advanced cancer.
Hurwitz HI; Dowlati A; Saini S; Savage S; Suttle AB; Gibson DM; Hodge JP; Merkle EM; Pandite L
Clin Cancer Res; 2009 Jun; 15(12):4220-7. PubMed ID: 19509175
[TBL] [Abstract][Full Text] [Related]
7. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
Robertson MJ; Mier JW; Logan T; Atkins M; Koon H; Koch KM; Kathman S; Pandite LN; Oei C; Kirby LC; Jewell RC; Bell WN; Thurmond LM; Weisenbach J; Roberts S; Dar MM
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4265-73. PubMed ID: 16857801
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma.
Pashenkov M; Goëss G; Wagner C; Hörmann M; Jandl T; Moser A; Britten CM; Smolle J; Koller S; Mauch C; Tantcheva-Poor I; Grabbe S; Loquai C; Esser S; Franckson T; Schneeberger A; Haarmann C; Krieg AM; Stingl G; Wagner SN
J Clin Oncol; 2006 Dec; 24(36):5716-24. PubMed ID: 17179105
[TBL] [Abstract][Full Text] [Related]
9. TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.
Inglefield JR; Dumitru CD; Alkan SS; Gibson SJ; Lipson KE; Tomai MA; Larson CJ; Vasilakos JP
J Interferon Cytokine Res; 2008 Apr; 28(4):253-63. PubMed ID: 18439103
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.
Leonard JP; Link BK; Emmanouilides C; Gregory SA; Weisdorf D; Andrey J; Hainsworth J; Sparano JA; Tsai DE; Horning S; Krieg AM; Weiner GJ
Clin Cancer Res; 2007 Oct; 13(20):6168-74. PubMed ID: 17947483
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist.
Vicari AP; Schmalbach T; Lekstrom-Himes J; Morris ML; Al-Adhami MJ; Laframboise C; Leese P; Krieg AM; Efler SM; Davis HL
Antivir Ther; 2007; 12(5):741-51. PubMed ID: 17713157
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.
Hotte SJ; Hirte HW; Chen EX; Siu LL; Le LH; Corey A; Iacobucci A; MacLean M; Lo L; Fox NL; Oza AM
Clin Cancer Res; 2008 Jun; 14(11):3450-5. PubMed ID: 18519776
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
[TBL] [Abstract][Full Text] [Related]
14. Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family.
Masci P; Olencki T; Wood L; Rybicki L; Jacobs B; Williams B; Faber P; Bukowski R; Tong K; Borden EC
Clin Pharmacol Ther; 2007 Mar; 81(3):354-61. PubMed ID: 17339865
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers.
Geller MA; Cooley S; Argenta PA; Downs LS; Carson LF; Judson PL; Ghebre R; Weigel B; Panoskaltsis-Mortari A; Curtsinger J; Miller JS
Cancer Immunol Immunother; 2010 Dec; 59(12):1877-1884. PubMed ID: 20820775
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
Papadopoulos KP; Goel S; Beeram M; Wong A; Desai K; Haigentz M; Milián ML; Mani S; Tolcher A; Lalani AS; Sarantopoulos J
Clin Cancer Res; 2008 Nov; 14(21):7110-5. PubMed ID: 18981010
[TBL] [Abstract][Full Text] [Related]
17. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
Mita MM; Mita AC; Chu QS; Rowinsky EK; Fetterly GJ; Goldston M; Patnaik A; Mathews L; Ricart AD; Mays T; Knowles H; Rivera VM; Kreisberg J; Bedrosian CL; Tolcher AW
J Clin Oncol; 2008 Jan; 26(3):361-7. PubMed ID: 18202410
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
Advani R; Forero-Torres A; Furman RR; Rosenblatt JD; Younes A; Ren H; Harrop K; Whiting N; Drachman JG
J Clin Oncol; 2009 Sep; 27(26):4371-7. PubMed ID: 19636010
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
Mita M; Mita A; Sarantopoulos J; Takimoto CH; Rowinsky EK; Romero O; Angiuli P; Allievi C; Eisenfeld A; Verschraegen CF
Cancer Chemother Pharmacol; 2009 Jul; 64(2):287-95. PubMed ID: 19034451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
